GlassScriptPhysician profile
Jeffery P Nelson
NPI 1417922212
$5,089.07
in general payments reported to CMS, 2019-2025
35 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $593 · 2021: $1,026 · 2022: $1,077 · 2023: $912 · 2024: $441 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,468.66 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Abbvie INC. | $653.10 | 2021-2025 | |
| Lilly USA, LLC | $303.79 | 2020-2023 | Reyvow, Emgality |
| Biogen, INC. | $286.55 | 2020-2025 | Vumerity, Spinraza |
| Novartis Pharmaceuticals Corporation | $262.35 | 2019-2025 | |
| Amgen INC. | $203.59 | 2021-2025 | Uplizna |
| Csl Behring | $198.33 | 2020-2025 | Hizentra, Privigen |
| Ucb, INC. | $176.44 | 2019-2025 | Nayzilam |
| Jazz Pharmaceuticals INC. | $154.40 | 2021-2025 | |
| Axsome Therapeutics, INC. | $146.24 | 2023-2025 | Sunosi |
| Allergan, INC. | $144.92 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $140.56 | 2020-2023 | |
| Stryker Corporation | $123.33 | 2019 | |
| Emd Serono, INC. | $106.29 | 2019-2021 | |
| Harmony Biosciences LLC | $81.31 | 2022-2024 | Wakix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $73.02 | 2019-2025 | Ultomiris |
| Sk Life Science, INC. | $55.35 | 2024-2025 | |
| Pfizer INC. | $50.50 | 2025 | |
| Exeltis, USA INC. | $38.80 | 2021-2025 | Slynd |
| Neurelis, INC. | $38.69 | 2025 | Valtoco |
| Millicent US INC | $37.52 | 2025 | Femlyv, Intrarosa |
| Neurocrine Biosciences, INC. | $34.93 | 2021-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $33.88 | 2020 | |
| Lundbeck LLC | $33.34 | 2020-2021 | |
| Eisai INC. | $33.21 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $31.42 | 2024-2025 | Lumryz |
| Scilex Pharmaceuticals INC. | $30.10 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.86 | 2023 | Xifaxan |
| Saol Therapeutics INC. | $27.91 | 2020 | |
| Tonix Medicines, INC. | $17.19 | 2025 | Zembrace Symtouch |
| Amneal Pharmaceuticals LLC | $16.42 | 2023 | Lioresal (Baclofen) |
| Grifols USA, LLC | $15.49 | 2023 | Gamunex-C |
| Celgene Corporation | $15.03 | 2023 | Zeposia |
| Acorda Therapeutics, INC | $14.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.27 | 2024 | Hyqvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.